Essilor's First-Half 2008 Results ( CHARENTON-LE-PONT France August ...)

Essilor's First-Half 2008 Results

Date:8/27/2008

CHARENTON-LE-PONT, France, August 28 /PRNewswire-FirstCall/ --

- A Solid First-Half Performance

- Net Profit Up 16.8% at Constant Exchange Rates

- Essilor Launches a Share Buyback Program

The Board of Directors of Essilor International, the world leader in ophthalmic optics, has approved the financial statements for the six months ended June 30, 2008.

EUR millions First-half 2008 First-half 2007 % change % change

at constant

exchange

rates

Revenue 1,520.2 1,476.9 +2.9% +9.6%

Contribution margin 18.2% 18.1% - -

Profit attributable 198.3 181.9 +9.0% +16.8%

to equity holders of

Essilor International

Basic earnings per 0.96 0.88(1) +8.1% +15.8%

share (in EUR)

(1) Adjusted for the two-for-one stock split on July 16, 2007

The highlights of the first half were:

- Growth (excluding the currency effect) of 9.6%

- Sustained business growth in North America, Latin America,

the ASEAN countries, China and India.

- Successful new products, notably the sixth-generation of

Transitions(R) variable-tint lenses and Crizal Avance(TM)

anti-reflective lenses with Scotchgard(TM) Protector.

- High profitability, with a contribution margin of 18.2% that

was slightly higher than the figure reported for full-year 2007.

- A 9% increase in profit attributable to equity holders of

Essilor International, for a net margin of 13%.

- An ongoing external growth strategy, with the acquisition of

13 companies representing approximately EUR70 million in full-year

revenue. '/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Biopure Announces 2008 Third Quarter Financial Results
2. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
3. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
6. Rosetta Genomics Reports Second Quarter 2008 Financial Results
7. VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance
8. Arno Therapeutics Announces Second Quarter 2008 Financial Results
9. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
10. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
11. Yongye Biotechnology International Announces Second Quarter Results

Post Your Comments:

Essilor's First-Half 2008 Results( CHARENTON-LE-PONT France August ...)